

Article Type: Review Article

Review

Title: Current and potential therapeutic strategies for the management of vascular calcification in patients with chronic kidney disease including those on dialysis

Authors: Irene Ruderman ^{1,2}, Stephen G. Holt ^{1,2}, Tim D. Hewitson ^{1,2}, Edward R. Smith ^{1,2} and Nigel D. Toussaint ^{1,2}

¹ Department of Nephrology, The Royal Melbourne Hospital and ² Department of Medicine (RMH), The University of Melbourne, Melbourne, Victoria, Australia

Corresponding Author:

Dr. Irene Ruderman
Department of Nephrology
The Royal Melbourne Hospital
300 Grattan St
Parkville 3050
Victoria, Australia

This is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the [Version of Record](#). Please cite this article as [doi: 10.1111/sdi.12710](https://doi.org/10.1111/sdi.12710)

This article is protected by copyright. All rights reserved

Phone: 03 9342 7000

Fax: 03 9347 1420

Email: irene.ruderman@mh.org.au

Author Manuscript

Authorship Page:

Authors

All authors contributed to the conception, critical appraisal and drafting of the work.

This article is protected by copyright. All rights reserved

All authors approved the final copy of the manuscript.

Disclosures

ERS has received research funding from Amgen, Baxter and Sanofi. NDT has received honoraria, travel support and research funding from Amgen, Shire and Sanofi. SGH has received honoraria, travel support or research funding from Amgen, Astra-Zenica, Gilead, Shire and Sanofi. IR and TDH declare that they have no competing interests.

Key words

Vascular calcification, chronic kidney disease, end-stage kidney disease, cardiovascular mortality

Abbreviations:

ALP alkaline phosphatase

CKD chronic kidney disease

CPP calciprotein particles

CRP C-reactive protein

CVD cardiovascular disease

ESKD end-stage kidney disease

MGP matrix Gla protein

PTH parathyroid hormone

RCT randomized controlled trial

SHPT secondary hyperparathyroidism

VC vascular calcification

Abstract

Patients with chronic kidney disease (CKD) have accelerated vascular stiffening contributing significantly to excess cardiovascular morbidity and mortality.

Much of the arterial stiffening is thought to involve vascular calcification (VC), but the pathogenesis of this phenomenon is complex, resulting from a disruption of the balance between promoters and inhibitors of calcification in a uremic milieu, along with derangements in calcium and phosphate metabolic pathways.

Management of traditional cardiovascular risk factors to reduce VC may be influential but has not been shown to significantly improve mortality. Control of mineral metabolism may potentially reduce the burden of VC, although using conventional approaches of restricting dietary phosphate, administering phosphate binders, and use of active vitamin D and calcimimetics, remains controversial because recommended biochemical targets are hard to achieve and clinical relevance hard to define. Increasing time on dialysis is perhaps another therapy with potential effectiveness in this area. Despite current treatments, cardiovascular morbidity and mortality remain high in this group. Novel therapies for addressing VC include magnesium and vitamin K supplementation, which are currently being investigated in large randomized control trials. Other therapeutic targets include crystallization inhibitors, ligand trap for activin receptors and BMP-7. This review summarizes current treatment strategies and therapeutic targets for the future management of VC in patients with CKD.

Introduction

Vascular calcification (VC) is highly prevalent in patients with chronic kidney disease (CKD) and advancing age but can also be seen in other groups including those with diabetes mellitus and chronic inflammatory conditions.

Observational studies report VC present in up to 25% of patients with CKD stage 3 and over 50% in patients on dialysis¹. Once present, VC progresses rapidly, irrespective of age^{2,3}. Two types of VC are identified in patients with

CKD⁴. Intimal calcification is associated with atherosclerotic plaques and its presence increases the risk of plaque erosion and rupture. Additionally, medial calcification in large elastic arteries and arterioles results in increased arterial stiffness and cardiac afterload⁵⁻⁷. These subtypes are not mutually exclusive and often co-exist. In large epidemiological studies VC is associated with increased cardiovascular mortality⁸ and morbidity⁹ as well as reduced bone mineral density (BMD) and increased fracture risk¹⁰. However, the precise mechanisms that link radiological or histological findings of VC and enhanced mortality remain speculative.

The pathophysiology of VC is likely to be a result of multiple interlinked mechanisms, some of which include phenotypic changes in cells, cell death, elastic degradation, calcinosis and passive deposition of calcium, in addition to changes in calcification inhibitors and possibly promoters¹¹. The initial triggers for calcification remain unknown but likely depend upon the type of calcification (intimal versus medial) and the location of the vessel, since VC proceeds at different rates in different areas. In patients with CKD, and especially end-stage kidney disease (ESKD), a significant contribution to VC is likely to result from a reduction in calcification inhibitors in association with deranged calcium and phosphate metabolism.

Numerous experimental studies show how vascular smooth muscle cells (VSMCs) can transform to an osteoblast-like phenotype¹², with the ability to produce collagenous extracellular matrix on to which mineral is deposited^{13,14}. This differentiation of VSMCs is characterized by expression of genes that are normally restricted to bone, such as bone morphogenetic protein 2 (BMP-2), osterix, runt-related transcription factor 2 (RUNX2) and alkaline phosphatase (ALP)¹⁵, although whether VC is the cause or effect of this upregulation remains contentious¹⁶. Expression of these osteoblastic genes is accompanied by

downregulation of VSMC lineage markers, such as transgelin and calponin¹⁷. Patients with CKD also develop a pro-inflammatory milieu, with increased C-reactive protein [CRP] and interleukin-6 [IL-6], and this may contribute to endothelial dysfunction and to the development of enhanced soft tissue calcification.

A key systemic inhibitor of VC is the circulating phosphoglycoprotein fetuin-A. This protein inhibits VC by binding to nascent nanoparticles of calcium and phosphate in the circulation, preventing mineral accretion. These particles are known as calciprotein particles (CPP) and may provide an important pathway for mineral transport and clearance. Chronic dysregulation of mineral metabolism, such as in CKD, results in accumulation and transformation of these particles from amorphous fetuin-calcium-phosphate (CPP1) to larger, more crystalline, particles (CPP2). Whilst cellular uptake of CPP1 causes little in the way of cellular responses, uptake of CPP2 results in phenotypic change¹⁸ and inflammatory cytokine release in some cells¹⁹. In observational studies, increased serum CPP²⁰ and specifically CPP2 are associated with increased VC and mortality in patients with CKD²¹.

At a tissue level, important VC inhibitors include endogenous pyrophosphate and carboxylated matrix Gla protein (MGP). Pyrophosphate binds to mineralization surfaces to prevent crystal growth, and extracellular levels are tightly regulated by tissue nonspecific alkaline phosphatase (TNAP). TNAP is vital for healthy skeletal development, and a fine balance exists in order to maintain calcification within specific tissue confines. MGP is another key protein expressed by chondrocytes and VSMC. It requires vitamin K as an essential cofactor for enzymatic carboxylation and function. MGP inhibits calcification by binding to and inactivating pro-mineralization BMP2^{22,23}, as well as having a direct effect on hydroxyapatite formation²⁴. As more is

discovered about VC, it is likely that there are interlinked mechanisms and multiple pathways between various calcification inhibitors, which work together to prevent this pathological process in healthy adults. Figure 1 highlights identified inhibitors and inducers of VC.

Patients with CKD have increased cardiovascular mortality and morbidity due to the presence of both traditional (e.g. hypertension and diabetes) and non-traditional cardiovascular risk factors (e.g. albuminuria and deranged calcium phosphate metabolism)^{25,26}. Many therapeutic interventions applicable to the general population to reduce cardiovascular disease burden, have had limited success when applied to the CKD population. Further research is underway to better understand the underlying pathophysiology. This review will summarize the current therapeutic strategies used for prevention and management of VC in patients with CKD. We will also discuss novel targets and future directions for the management of VC.

Current therapeutic strategies to reduce VC

General cardiovascular risk reduction

Compared to the general population, patients with CKD have a higher prevalence of many traditional cardiovascular risk factors, including hypertension, diabetes and hypertriglyceridemia²⁷. Reduction of traditional cardiovascular risk factors may play a management role in this patient population, but the complex interplay and direction of causality between renal impairment and cardiovascular disease remains enigmatic²⁸. Few studies have looked specifically at risk factor modification in patients with CKD, and most evidence is derived from *post hoc* analyses or meta-analyses.

Nevertheless, blood pressure management plays a significant role in attempting to retard the progression of CKD stages 2-5 and complications in CKD stage 5D. The international Kidney Disease Improving Global Outcomes (KDIGO) guidelines recommend targeting a blood pressure of ≤ 140 mmHg systolic and ≤ 90 mmHg diastolic for patients without albuminuria and ≤ 130 mmHg systolic and ≤ 80 mmHg diastolic for patients with albuminuria²⁹ in CKD. Blood pressure targets become more difficult to recommend once patients commence dialysis, although two meta-analyses^{30,31} reported benefits of antihypertensive therapy compared to placebo for cardiovascular protection in hemodialysis patients. There is no evidence that antihypertensive therapy affects VC but may reduce myocardial fibrosis and left ventricular hypertrophy.

Lipid profiles in patients with CKD vary significantly from the general population, typically with higher levels of triglycerides and low high-density lipoprotein (HDL). Low HDL may contribute to complex inflammatory and oxidative stress pathways and may exacerbate uremic endothelial dysfunction³². Use of cholesterol-lowering statin therapy in patients with CKD, as in the general population, has been found to reduce cardiovascular mortality, with a recent meta-analysis reporting that statins result in a reduced risk - relative risk (RR) 0.72 (95% confidence interval [CI]; 0.66-0.79) for major cardiovascular events³³. However, the benefit of statins on dialysis is less clear, with lipid lowering inconsistently improving cardiovascular outcomes. Only one of three randomized controlled trials (RCTs) showed a statistically significant effect in dialysis patients (SHARP³⁴ using statin plus ezetemibe), whilst two others failed to find an effect (AURORA³⁵ and the 4D³⁶ trials). No RCT evidence supports the use of fibrates in patients with CKD. There are reasonable data linking some other traditional cardiovascular risk factors, like diabetic control

and smoking, to suggest that intervention may be of value in dialysis patients and guidelines are as for the general population.

Improving abnormalities of mineral metabolism

Phosphate-lowering therapy:

Observational studies have shown significant and independent associations between elevated serum phosphate levels and all-cause mortality and cardiovascular disease in people with normal kidney function and in patients with CKD. This relationship has been consistently reported across the spectrum of CKD from mild renal impairment to patients with ESKD on dialysis^{37,38}. Despite these associations, mechanisms and the direction of causality by which elevated serum phosphate are associated with vascular disease and death remain unclear. They may involve endothelial dysfunction, enhanced extra-osseous calcium apatite deposition or energy pathway disruption.

Management of hyperphosphatemia in CKD has involved dietary phosphate restriction, the use of phosphate binders and dialysis. Prescription of phosphate binders has become routine in dialysis patients, although it is becoming increasingly controversial, and there remain conflicting views on their role and serum phosphate targets. An early RCT, the Treat-to-Goal study, reported greater aortic and coronary artery VC progression in 200 prevalent dialysis patients receiving calcium-based phosphate binders compared with sevelamer³⁹. At study completion, the median absolute calcium score in the coronary arteries ($p=0.03$) and aorta ($p=0.01$) increased significantly in calcium-treated compared to sevelamer-treated subjects. The median change in calcium score was higher with calcium-based binders compared with sevelamer in coronary arteries (25% vs. 6%, $p=0.02$) and the aorta (28% vs. 5%, $p=0.02$). The results

were congruent in the Renagel in New Dialysis (RIND) study of sevelamer vs calcium-based binders in 129 incident hemodialysis patients over 18 months with pre-existing coronary artery calcification (CAC)^{40,41}. This study reported a lower mortality in the non-calcium arm compared to the calcium-based binder arm.

Sevelamer may also have effects beyond phosphate binding, such as increasing fetuin-A levels ($p < 0.001$) and improving flow mediated dilation (FMD) ($p < 0.001$)⁴². In the Calcium Acetate Renagel Evaluation-2 (CARE-2) study⁴³ of 203 prevalent hemodialysis patients, there was no difference in CAC after one year of follow up between the two study arms involving atorvastatin plus either sevelamer or calcium acetate (mean increase 35% in the calcium acetate group vs 39% in the sevelamer group; 95% CI, 0.851-1.161).

A number of systematic reviews have been performed and one study of 77 trials (12,562 participants) compared phosphate binding agents in adults with CKD and concluded that there was insufficient evidence that any drug class lowered mortality or cardiovascular events compared to placebo⁴⁴. However, compared to calcium, sevelamer did appear to reduce all-cause mortality (odds ratio [OR], 0.39; 95% CI 0.21-0.74). A similar meta-analysis of 71 RCTs assessing phosphate binder use in dialysis patients failed to find a statistically significant difference in cardiovascular mortality between the calcium and non-calcium based binders (RR 2.54, 95% CI 0.67-9.62)⁴⁵. An earlier meta-analysis of phosphate binders in patients with CKD concluded that non-calcium based binders were associated with a 22% reduction in all-cause mortality based on 18 studies of over 700 patients (risk ratio 0.78, 95% CI 0.61-0.98)⁴⁶.

In the pre-dialysis CKD population however, there is less evidence for the role of phosphate binders. A recent RCT by Block *et al* compared phosphate binders

(sevelamer, lanthanum and calcium-based) with placebo in patients with CKD stages 3-4 over 9 months and reported minimal decline in serum phosphate within the active treatment groups and, in fact, increases in CAC for the combined phosphate binder groups⁴⁷. Although the greatest increase in VC was seen in patients on the calcium-based binders, these results question the efficacy and safety of phosphate binders in this population with normal serum phosphate levels.

Although studies relating to this issue are conflicting and the case for phosphate binders *per se* has not yet been proven, the most consistent finding, limiting exogenous calcium, has been recommended in the current KDIGO Chronic Kidney Disease Mineral and Bone Disorder (CKD-MBD) guidelines.⁴⁸

Currently a number of studies are being conducted to assess the impact of phosphate binders in CKD, including the IMpact of Phosphate Reduction On Vascular End-points in Chronic Kidney Disease (IMPROVE-CKD) trial, assessing vascular compliance and VC in patients with CKD stage 3b and 4 with lanthanum carbonate versus placebo. This trial will, it is hoped, be informative in addressing whether early phosphate binder use will confer any vascular protection in pre-dialysis CKD patients.

Calcimimetics:

Calcimimetics act to allosterically modulate the calcium sensing receptor (CaR). The CaR is a G-protein coupled receptor expressed in a variety of tissues including the parathyroid gland and VSMC. In the vasculature, it may exert a physiological role by controlling arterial function and contributes to development of VC. As renal function declines, there is down regulation of the CaR. In animal models, cinacalcet markedly attenuates vascular remodeling and calcification⁴⁹⁻⁵² and proposed mechanisms include abrogating endothelial to

mesenchymal cell transition⁴⁹, reduced expression of osteoblastic genes⁵⁰, activation of the CaR in endothelial and VSMCs⁵¹, and upregulation of MGP expression⁵³⁻⁵⁵.

Calcimimetics are used for the treatment of secondary hyperparathyroidism (SHPT) in patients with ESKD, with two available preparations: oral cinacalcet and a new intravenous formulation, etelcalcitide. Cinacalcet has been associated with reduced progression of abdominal aortic calcification over a 12-month period⁵⁶. In a *post hoc* analysis, Cunningham *et al*⁵⁷ combined data on clinical outcomes from four RCTs and showed that treatment with cinacalcet resulted in a significant reduction in the risk of cardiovascular hospitalization (hazard ratio [HR] 0.61, 95% CI 0.43-0.86). The effect of calcimimetics on VC was seen in the ADVANCE study (A Randomized Study to Evaluate the Effects of Cinacalcet Plus Low Dose Vitamin D on Vascular Calcification in Subjects with CKD)⁵⁸. In this study, 360 hemodialysis patients with SHPT were treated with either cinacalcet plus low dose vitamin D, or flexible doses of vitamin D alone. A stratified median treatment difference in aortic valve calcification was seen in the cinacalcet group (-44.7%; 95% CI -85.8% - -6.1%, p=0.01), along with a trend to lower CAC scores in the cinacalcet plus vitamin D group (median increase of 24%) compared to the vitamin D group (median increase of 31%, p=0.073). A major limitation was the short 12-month duration of this study, which was unlikely to be sufficient for the detection of substantial changes in VC.

Despite the possible benefits on VC, cardiovascular benefits of calcimimetics were inconclusive in the Effect of Cinacalcet on Cardiovascular disease in Patients Undergoing Dialysis (EVOLVE) trial⁵⁹, which to date remains the largest RCT conducted in a dialysis population (3883 participants). This trial failed to show a difference in primary composite end point (death, myocardial

infarction, hospitalization for unstable angina, heart failure or peripheral vascular event) in the cinacalcet compared to placebo group (HR 0.93, 95% CI 0.85-1.02, p=0.11). Results of this trial however should be interpreted with caution because of numerous limitations including a relatively low expected event rate in the age group studied and high study treatment cross over (significant drop-in and drop-out rate) due to commercially available cinacalcet. Although the primary analysis of the EVOLVE trial was negative, *post hoc* analyses demonstrated reduced incidence of calcific uremic arteriolopathy (CUA) (unadjusted HR, 0.31; 95% CI, 0.13-0.79; p=0.014)⁶⁰, a trend towards reduced fracture rate (adjusted HR 0.83 (95% CI, 0.72-0.98)⁶¹ and decreased risk of death and cardiovascular events, although the latter benefit only in patients over the age of 65 years (adjusted HR 0.7, 95% CI 0.6-0.81)⁶².

Surgical management of SHPT has, however, failed to demonstrate a protective effect on VC. A recent prospective observational study of 19 hemodialysis patients with severe SHPT reported that parathyroidectomies resulted in increased CAC (p=0.02) and were associated with a shift from high to low bone turnover disease on bone biopsy over a 12-month period (90% of patients evolved to either very low or low bone turnover)⁶³. The presence of low bone turnover disease has previously been associated with a substantially increased risk of VC⁶⁴.

Vitamin D:

In observational studies of patients with CKD^{65,66} and the general population⁶⁷, 25-hydroxy vitamin D (25[OH]D) deficiency has been associated with VC, arterial stiffness and cardiovascular mortality. Cardiovascular benefits of nutritional vitamin D supplementation may result from altered vascular oxidative stress, smooth muscle function or improvement in left ventricular

mass index⁶⁸. Treatment of VSMCs with vitamin D receptor analogs has been associated with inhibition of osteogenic processes⁶⁹ as well as anti-inflammatory effects^{70,71} and increasing endothelial cell nitric oxide production⁷². In animal models, physiological doses of vitamin D supplementation have shown protective effects against VC⁷³, but excessive 25(OH)D or active vitamin D can result in VC⁷⁴.

In patients with CKD and those on dialysis, the efficacy of both nutritional vitamin D and active vitamin D treatment on vascular health has been investigated; however, beneficial effects are uncertain. Presently there is inconsistent evidence and conflicting literature regarding the form and dose of vitamin D supplementation. Of three recent RCTs⁷⁵⁻⁷⁷ examining the role of both nutritional and active vitamin D supplementation on markers of vascular stiffness in non-dialysis CKD patients, only two^{75,76} reported improvement in surrogate markers of vascular stiffness (pulse wave velocity [PWV]) with nutritional vitamin D supplementation but not active vitamin D. The KDIGO CKD-MBD guidelines recommend nutritional vitamin D for treatment of 25(OH)D deficiency but not routine use of calcitriol or vitamin D receptor analogs in pre-dialysis patients, given the risk of hypercalcemia and likely associated pro-calcific effects, unless prescribed cautiously for severe and progressive SHPT⁴⁸.

Bisphosphonates

Bisphosphonates are synthetic analogues of pyrophosphate and inhibit osteoclast-mediated resorption as well as calcium-phosphate crystal deposition in bone. They have been used for treatment of osteoporosis over the past two decades but they may also play a role in inhibiting arterial calcification and in macrophage suppression in atheromatous lesions. Reports dating back to 1970's

in human ⁷⁸ and animal ⁷⁹ studies have shown that the early developed bisphosphonates, such as etidronate, inhibit ectopic calcification. Since then, animal models have suggested that these drugs may inhibit VC ^{80,81} without significant changes to other known cardiovascular risk factors like lipids ⁸².

However, human trials of bisphosphonates for the treatment of VC are sparse. In the general population, the largest study involved 474 elderly osteoporotic women treated for three years with ibandronate; it showed no effect on aortic calcification ⁸³. Smaller studies in patients with type 2 diabetes and osteopenia did show a reduction in carotid intima-media thickness with 12 months of etidronate versus placebo ($p < 0.005$) ⁸⁴. In the only RCT in the pre-dialysis CKD population, 18 months of weekly alendronate failed to demonstrate a difference in progression of CT-measured aortic VC (adjusted difference, -24.2 Hounsfield units, 95% CI, -77-28.6, $p = 0.4$) ⁸⁵. Three small Japanese trials assessed the use of low dose bisphosphonates on VC in hemodialysis patients. Etidronate administration for 12 months reduced ⁸⁶ or inhibited ⁸⁷ CAC progression, but was associated with an increased risk of osteomalacia ⁸⁸. In current clinical practice these medications are reserved for osteoporosis in patients with CKD stages 1-3 ⁴⁸, and potentially contraindicated for more advanced CKD due to possible risk of exacerbating adynamic bone disease, osteomalacia and SHPT.

Improving dialysis adequacy and renal transplantation

There is evidence to suggest more frequent and extended hours hemodialysis improves vascular physiology ⁸⁹ compared with conventional thrice weekly hemodialysis. This may be a result of better blood pressure control (with a reduction in antihypertensive medication requirement) ⁹⁰ and/or better management of SHPT and a reduction in serum phosphate levels which in most cases includes reduced prescription of phosphate binders and a more liberal diet

⁹¹. Extended hours and/or more frequent dialysis also augments uremic toxin clearance, which, in animal models, reduces endothelial injury and death ⁹².

In two prospective observational studies, conversion from conventional hemodialysis (CHD) to nocturnal hemodialysis (NHD) (6-9 hours per night for 3.5-4 sessions per week) for a 12-month period resulted in a non-significant 9% decrease in CAC scores ($p=0.1$) ⁹³ and improvement or stabilization in VC and ectopic calcification in 22 out of 26 patients on home dialysis as seen in hand and foot X-rays. There was also a reduction in serum phosphate and parathyroid hormone (PTH) ⁹⁴. In a case study supporting the benefit of improving dialysis adequacy, conversion from CHD to NHD led to symptom and improvement and increased blood flow in the lower limb vessels of a patient with refractory claudication ⁹⁵.

The role of renal transplantation in improving VC remains controversial. There are conflicting data on VC progression as evaluated by coronary artery imaging post transplantation, with studies showing reversal of calcification ⁹⁶, no change in CAC ⁹⁷, and also progression of disease ⁹⁸ depending on the population studied. Challenges in assessing post-transplant VC progression include the heterogeneity of transplant recipients (including age and dialysis vintage at time of transplant) which can contribute significantly to VC development and progression, as well as exclusion of patients with significant iliac artery calcification from transplantation. Post-transplant related diabetes and complications of immunosuppressive therapy also can have an impact on VC.

Future potential management for VC in clinical evaluation

Magnesium

Magnesium plays an important role in vascular health⁹⁹, with normal magnesium homeostasis in VSMC maintained via TRPM7 cation channels. Magnesium prevents post-transcriptional changes in VSMC differentiation and apoptosis^{100,101} and upregulates VC inhibitors (MGP and osteopontin)¹⁰², whilst counteracting expression of osteogenic transcription factors (BMP-2, RUNX2, Msh homeobox 2, and SRY- box 9), bone proteins and genes associated with matrix mineralization (osteocalcin and TNAP)¹⁰³. In animal models of VC, dietary supplementation with magnesium results in marked reduction in VC and mortality, improved mineral metabolism, including lowering of PTH, as well as improvement in renal function¹⁰⁴.

In the general population, higher dietary magnesium intake is associated with reduced all-cause mortality, stroke, heart failure and diabetes mellitus¹⁰⁵. Serum magnesium concentration < 0.8mmol/L has been associated with a 36% increased risk of death from coronary artery disease^{106,107} and two meta-analyses report serum magnesium is inversely associated with cardiovascular risk in both healthy controls and hemodialysis cohorts^{108,109}. Similar findings were seen in a study of 80 patients on peritoneal dialysis¹¹⁰, with higher serum magnesium associated with less abdominal aortic calcification ($R^2=0.06$, unstandardized coefficient[B]= -7.81, p=0.03). Magnesium has also been reported to delay CPP maturation and transition from primary to secondary CPP in hemodialysis patients¹¹¹ by slowing calcification propensity.

Currently, robust data on magnesium supplementation in the CKD population is lacking. Tzanakis *et al*¹¹² reported the largest RCT to date studying the effect of magnesium on VC. It compared the effect of the phosphate binder calcium acetate with and without magnesium carbonate on arterial calcification (evaluated by plain X-ray) in 72 hemodialysis patients and demonstrated

improved VC in the magnesium arm ($p=0.04$). On multivariate logistic regression analysis, serum magnesium was an independent predictor of slower progression of arterial calcification. There is an RCT underway (without the confounding use of calcium) assessing the effect of 30 mmol magnesium/day vs placebo on VC in patients with CKD stages 3-4 over a 12-month period ¹¹³. Table 1 summarizes interventional and observation clinical trials assessing magnesium supplementation in VC.

Vitamin K

Vitamin K is an essential cofactor in the enzymatic carboxylation of glutamate, and exists in two biologically active forms, vitamin K1 (phylloquinone, found in green leafy vegetables) and vitamin K2 (menaquinone, found in dairy products). Vitamin K is necessary for carboxylation and thus activation of clotting factors as well as several proteins involved in bone matrix formation (osteocalcin [OC]), inhibition of soft tissue mineralization (MGP) and prevention of VSMC apoptosis (growth arrest specific 6 protein [GAS6]). In animal studies, vitamin K2 supplementation reduces VC, via enhancement of MGP carboxylation ¹¹⁴ and MGP mRNA expression ¹¹⁵ in tissues.

Deficiency of active vitamin K in the general population has been associated with increased aortic stiffness as measured by PWV ¹¹⁶, as well as VC ¹¹⁷ and increased all-cause mortality ¹¹⁸ in hemodialysis patients. Greater rates of vitamin K deficiency or activation are consistently identified in dialysis populations with dietary questionnaires identifying reduced daily intake of phylloquinone and or menaquinone; in some cohort studies deficiency is present in up to 30% of patients ^{119,120}. One possible cause for this may be the use of phosphate binders. *In vitro* studies suggest that and many commonly used phosphate binders (including lanthanum and calcium carbonate) can sequester

vitamin K in the gut preventing its absorption. Only sucroferric-oxyhydroxide and sevelamer carbonate do not appear to bind much vitamin K ¹²¹.

Vitamin K supplementation has been trialed in patients with CKD including those on hemodialysis. CKD patients given 90mcg/day of vitamin K2 supplementation, combined with 10mcg of nutritional vitamin D, for 270 days had significantly lower carotid intimal thickness compared to those with vitamin D supplementation alone (p=0.005) ¹²². In patients on hemodialysis, short duration of vitamin K2 supplementation (4-6 weeks) at a dose of 360mcg/day reduces markers of vitamin K deficiency [uncarboxylated MGP ¹²³, uncarboxylated OC and protein induced by vitamin K absence (PIVKA-II) levels], whilst also being safe and well tolerated ¹²⁴. Currently there is a large multicenter RCT recruiting incident hemodialysis patients (Inhibiting the progression of arterial calcification with vitamin K in HemoDialysis patients [iPACK-HD]) comparing 10mg vitamin K1 treatment thrice weekly versus placebo, with the primary endpoint as change in CAC over one year of therapy ¹²⁵. Another clinical trial is also underway evaluating the effect of vitamin K1 compared to placebo on CUA (ClinicalTrials.gov identifier NCT02278692) ¹²⁶.

Mineralocorticoid receptor antagonists (MRA)

Following the discovery of mineralocorticoid excess in Klotho deficient mice with accelerated VC, research interest has increased in the role of hyperaldosteronism triggering osteoinductive changes in the vasculature. In both human and animal studies, hyperaldosteronism is associated with vascular stiffness, damage and accelerated atherosclerosis ¹²⁷⁻¹²⁹. VSMCs have intracellular mineralocorticoid receptors (MRs) ¹³⁰ as well as aldosterone synthase, an enzyme involved in the synthesis of mineralocorticoids, which is upregulated in a high phosphate environment ¹³¹. Stimulation of the MR by

circulating aldosterone from the adrenal glands or locally produced aldosterone¹³² triggers osteoblast signaling pathways¹³³⁻¹³⁵ by upregulating the type 3 sodium dependent phosphate transporter PIT1, and upregulating expression of osteoblastic transcription factors in VSMCs and expression of TNAP, leading to reduction of local pyrophosphate. Aldosterone also has other cellular effects including upregulating BMP2¹³³ and TNF α ¹²⁹, perhaps further contributing to VC.

In vitro, mineralocorticoid receptor antagonists (MRAs) ameliorate phosphate-induced osteogenic transformation¹³¹ in human aortic VSMCs. A recent systematic review¹³⁶ incorporating nine trials of 829 patients with ESKD found MRAs were associated with a 66% RR reduction in cardiovascular mortality compared with controls (RR 0.34; 95% CI 0.15-0.75). However, there was an associated 3-fold increase in the risk of hyperkalemia. Due to the small size and heterogeneity of the studies collected, the data were not robust enough to determine the true benefit of MRAs in patients with ESKD; two larger RCTs are underway currently to further delineate the benefit of MRAs in patients on dialysis. SpinD (ClinicalTrials.gov identifier NCT02285920)¹³⁷ is a 125-patient pilot trial assessing the comparative safety and tolerability of three different doses of spironolactone versus placebo and ALCHEMIST (ALdosterone Antagonist Chronic HEModialysis Interventional Survival Trial, (ClinicalTrials.gov identifier NCT01848639)¹³⁸ is an 825-patient European trial assessing cardiovascular mortality in dialysis patients with spironolactone therapy.

Sodium Thiosulphate

Sodium thiosulphate, primarily used for the treatment of cyanide poisoning, has become an adjunctive treatment for CUA. It is said to participate in a cation

exchange reaction with calcium in insoluble tissue deposits, leading to more soluble calcium thiosulphate. However, this mechanism is unlikely since it does not explain why sodium thiosulphate does not appear to chelate circulating calcium; any benefit may simply be due to its induction of a metabolic acidosis. Sodium thiosulphate was initially trialed for recurrent nephrocalcinosis in the 1980's with some reports of success^{139,140}. In CUA, sodium thiosulphate is thought to have antioxidant properties with generation of glutathione and prevention of reactive oxygen species thereby reversing endothelial dysfunction¹⁴⁰. However, long term use of sodium thiosulphate is hampered by the development of metabolic acidosis¹⁴¹ as a major side effect.

Two trials to date have evaluated sodium thiosulphate in the treatment of VC. Matthews *et al*¹⁴² assessed the effect of sodium thiosulphate on CAC (Agaston score > 50) in 22 hemodialysis patients over a five-month period. At trial conclusion there was no mean annualized rate of change in VC in the cohort although individual analysis showed calcification progression in 14 out of 22 subjects. The main reported adverse effect was nausea and vomiting although these symptoms were managed by reduction in dose of medication. In the second study, 87 stable patients on hemodialysis with CAC scores of ≥ 300 received intravenous sodium thiosulphate, 12.5mg twice weekly post dialysis, for four months¹⁴³. Despite a statistically significant reduction in VC progression, treatment was associated with a decline in hip BMD and a high side effect profile likely as a result of worsening metabolic acidosis. A clinical trial currently recruiting will evaluate the effects of IV Sodium Thiosulphate compared to placebo in patients with CUA (ClinicalTrials.gov identifier NCT03150240)¹⁴⁴

A summary of completed interventional clinical trials looking at novel agents for VC is presented in Table 2.

Novel targets for other potential future therapies of VC

Crystallization inhibitors

Crystallization inhibitors are a new class of drug that may prove to be beneficial in the treatment of VC. They work by obstructing or preventing crystal development, much like pyrophosphate or bisphosphonates, by binding to the crystal nucleus or the apatite crystal face to disturb its development without any cellular signaling capacity. Currently under development is SN472, an intravenous formulation of myo-inositol hexaphosphate, a small, highly water-soluble molecule. In animal models, this drug has been effective in reducing VC^{145,146}. The use of SNF472 on progression of VC in hemodialysis patients is currently being evaluated in a phase 2 clinical trial (ClinicalTrials.gov identifier NCT02966028)¹⁴⁷.

Ligand trap for the activin type IIA receptor (ActRIIa) and bone morphogenetic protein 7 (BMP 7)

Activin and BMP7 protein are part of the TGF β superfamily. Both of these proteins can bind to ActRIIa receptors on the cell surface leading to regulation of gene transcription¹⁴⁸. Activin-A is normally expressed in bone, however if it binds to ActRIIa receptors in VSMCs it can inhibit BMP7 signaling which results in transdifferentiation of the VSMC into an osteoblastic phenotype. Activin-A upregulation can occur in CKD and is thought to contribute to increased bone remodeling.

In vivo trials of ligand trap for ActRIIa in an animal model of atherosclerosis reported downregulation of ActRIIa signaling with a resultant decrease in atherosclerotic calcification as well as decreased expression of osteoblastic proteins and increased levels of smooth muscle cell specific proteins¹⁴⁹. Other beneficial effects of this drug included increased levels of klotho, reduced renal fibrosis¹⁴⁹, and improvement in bone changes associated with CKD¹⁵⁰. Animal and *in vitro* human studies of BMP7 therapy have also been promising in attenuating VC^{151,152}. Figure 2 summarizes the mechanism of action of new therapeutics for VC.

Conclusion

VC is a complex pathological process that occurs as part of ageing but can be accelerated in many pathological conditions including CKD, inflammatory disorders and diabetes. In patients with CKD some of the mechanisms to account for this phenomenon include disruption to calcium and phosphate metabolic pathways, together with an imbalance of promoters and inhibitors of calcification which can tip the balance towards a pro-calcific milieu. Once VC is established it is unlikely to be reversed and management should be based on slowing its progression. By the time VC is evident radiologically, opportunities to intervene in its pathogenesis may have been missed. Therefore, there needs to be a focus on identification of early markers of micro-calcification as well as research on the cohort of patients with ESKD without radiological evidence of calcification. These patients may have intrinsic protection and or genetic resistance to this pathology that we could harness therapeutically.

Current treatment is challenging but perhaps should be aimed at addressing multiple physiological targets; addressing traditional vascular risk factors may

play a role but it is likely we need to further understand and address mineral stress pathways. Large clinical trials are currently underway looking at the potential benefits of vitamin K and magnesium supplementation and these hold promise for future management. Novel treatment targets on the horizon include crystallization inhibitors, ligand trap for ActRIIa and BMP7 protein. Ongoing and future clinical trials assessing VC reduction in the CKD population are desperately needed to improve cardiovascular and mortality outcomes in these high-risk patients.

Author Manuscript

References:

1. Sigrist MK, Taal MW, Bungay P, McIntyre CW. Progressive vascular calcification over 2 years is associated with arterial stiffening and increased mortality in patients with stages 4 and 5 chronic kidney disease. *Clin J Am Soc Nephrol.* 2007;2(6):1241-1248.
2. Shroff RC, McNair R, Figg N, et al. Dialysis accelerates medial vascular calcification in part by triggering smooth muscle cell apoptosis. *Circulation.* 2008;118(17):1748-1757.
3. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. *American journal of kidney diseases : the official journal of the National Kidney Foundation.* 1998;32(5 Suppl 3):S112-119.
4. Goodman WG. Vascular calcification in end-stage renal disease. *J Nephrol.* 2002;15 Suppl 6:S82-85.
5. Virmani R, Burke AP, Kolodgie FD, Farb A. Vulnerable plaque: the pathology of unstable coronary lesions. *Journal of interventional cardiology.* 2002;15(6):439-446.

6. London GM, Marchais SJ, Guerin AP. Arterial stiffness and function in end-stage renal disease. *Advances in chronic kidney disease*. 2004;11(2):202-209.
7. Abedin M, Tintut Y, Demer LL. Vascular calcification: mechanisms and clinical ramifications. *Arteriosclerosis, thrombosis, and vascular biology*. 2004;24(7):1161-1170.
8. London GM, Guerin AP, Marchais SJ, Metivier F, Pannier B, Adda H. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. *Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association*. 2003;18(9):1731-1740.
9. Lehto S, Niskanen L, Suhonen M, Ronnema T, Laakso M. Medial artery calcification. A neglected harbinger of cardiovascular complications in non-insulin-dependent diabetes mellitus. *Arteriosclerosis, thrombosis, and vascular biology*. 1996;16(8):978-983.
10. Braun J, Oldendorf M, Moshage W, Heidler R, Zeitler E, Luft FC. Electron beam computed tomography in the evaluation of cardiac calcification in chronic dialysis patients. *American journal of kidney diseases : the official journal of the National Kidney Foundation*. 1996;27(3):394-401.
11. Reynolds JL, Joannides AJ, Skepper JN, et al. Human vascular smooth muscle cells undergo vesicle-mediated calcification in response to changes in extracellular calcium and phosphate concentrations: a potential mechanism for accelerated vascular calcification in ESRD. *Journal of the American Society of Nephrology : JASN*. 2004;15(11):2857-2867.
12. Giachelli CM. Vascular calcification mechanisms. *Journal of the American Society of Nephrology : JASN*. 2004;15(12):2959-2964.
13. Shanahan CM, Crouthamel MH, Kapustin A, Giachelli CM. Arterial calcification in chronic kidney disease: key roles for calcium and phosphate. *Circ Res*. 2011;109(6):697-711.
14. Ciceri P, Volpi E, Brenna I, et al. Combined effects of ascorbic acid and phosphate on rat VSMC osteoblastic differentiation. *Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association*. 2012;27(1):122-127.
15. Jono S, McKee MD, Murry CE, et al. Phosphate regulation of vascular smooth muscle cell calcification. *Circ Res*. 2000;87(7):E10-17.

16. O'Neill WC. Understanding the pathogenesis of vascular calcification: timing is everything. *Kidney international*. 2017;92(6):1316-1318.
17. Steitz SA, Speer MY, Curinga G, et al. Smooth muscle cell phenotypic transition associated with calcification: upregulation of Cbfa1 and downregulation of smooth muscle lineage markers. *Circ Res*. 2001;89(12):1147-1154.
18. Holt SG, Smith ER. Fetuin-A-containing calciprotein particles in mineral trafficking and vascular disease. *Nephrology Dialysis Transplantation*. 31(10):1583-1587.
19. Smith ER, Hanssen E, McMahon LP, Holt SG. Fetuin-A-containing calciprotein particles reduce mineral stress in the macrophage. *PLoS ONE [Electronic Resource]*. 8(4):e60904.
20. Hamano T, Matsui I, Mikami S, et al. Fetuin-mineral complex reflects extraosseous calcification stress in CKD. *Journal of the American Society of Nephrology : JASN*. 2010;21(11):1998-2007.
21. Smith ER, Ford ML, Tomlinson LA, et al. Serum calcification propensity predicts all-cause mortality in predialysis CKD. *Journal of the American Society of Nephrology*. 25(2):339-348.
22. Sweatt A, Sane DC, Hutson SM, Wallin R. Matrix Gla protein (MGP) and bone morphogenetic protein-2 in aortic calcified lesions of aging rats. *Journal of thrombosis and haemostasis : JTH*. 2003;1(1):178-185.
23. Zhang YT, Tang ZY. Research progress of warfarin-associated vascular calcification and its possible therapy. *Journal of cardiovascular pharmacology*. 2014;63(1):76-82.
24. Roy ME, Nishimoto SK. Matrix Gla protein binding to hydroxyapatite is dependent on the ionic environment: calcium enhances binding affinity but phosphate and magnesium decrease affinity. *Bone*. 2002;31(2):296-302.
25. Foley RN, Parfrey PS, Sarnak MJ. Epidemiology of cardiovascular disease in chronic renal disease. *Journal of the American Society of Nephrology : JASN*. 1998;9(12 Suppl):S16-23.
26. Lindner A, Charra B, Sherrard DJ, Scribner BH. Accelerated atherosclerosis in prolonged maintenance hemodialysis. *The New England journal of medicine*. 1974;290(13):697-701.
27. Longenecker JC, Coresh J, Powe NR, et al. Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: the CHOICE Study. *Journal of the American Society of Nephrology : JASN*. 2002;13(7):1918-1927.

28. Tomlinson LA, Holt SG. Is the kidney just a modified blood vessel? Unravelling the direction of causality between cardiovascular and renal disease. *Atherosclerosis*. 2011;216(2):275-276.
29. Wheeler DC, Becker GJ. Summary of KDIGO guideline. What do we really know about management of blood pressure in patients with chronic kidney disease? *Kidney international*. 2013;83(3):377-383.
30. Agarwal R, Sinha AD. Cardiovascular protection with antihypertensive drugs in dialysis patients: systematic review and meta-analysis. *Hypertension (Dallas, Tex : 1979)*. 2009;53(5):860-866.
31. Heerspink HJL, Ninomiya T, Zoungas S, et al. Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials. *The Lancet*. 2009;373(9668):1009-1015.
32. Keane WF, Tomassini JE, Neff DR. Lipid Abnormalities in Patients with Chronic Kidney Disease: Implications for the Pathophysiology of Atherosclerosis. *Journal of Atherosclerosis and Thrombosis*. 2013;20(2):123-133.
33. Palmer SC, Navaneethan SD, Craig JC, et al. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. *The Cochrane database of systematic reviews*. 2014(5):Cd007784.
34. Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. *Lancet*. 2011;377(9784):2181-2192.
35. Fellstrom BC, Jardine AG, Schmieder RE, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. *The New England journal of medicine*. 2009;360(14):1395-1407.
36. Wanner C, Krane V, Marz W, et al. Randomized controlled trial on the efficacy and safety of atorvastatin in patients with type 2 diabetes on hemodialysis (4D study): demographic and baseline characteristics. *Kidney Blood Press Res*. 2004;27(4):259-266.
37. Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. *American journal of kidney diseases : the official journal of the National Kidney Foundation*. 1998;31(4):607-617.

38. Kestenbaum B, Sampson JN, Rudser KD, et al. Serum phosphate levels and mortality risk among people with chronic kidney disease. *Journal of the American Society of Nephrology : JASN*. 2005;16(2):520-528.
39. Chertow GM, Burke SK, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. *Kidney international*. 2002;62(1):245-252.
40. Block GA, Raggi P, Bellasi A, Kooienga L, Spiegel DM. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. *Kidney international*. 2007;71(5):438-441.
41. Block GA, Spiegel DM, Ehrlich J, et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. *Kidney international*. 2005;68(4):1815-1824.
42. Caglar K, Yilmaz MI, Saglam M, et al. Short-Term Treatment with Sevelamer Increases Serum Fetuin-A Concentration and Improves Endothelial Dysfunction in Chronic Kidney Disease Stage 4 Patients. *Clinical Journal of the American Society of Nephrology : CJASN*. 2008;3(1):61-68.
43. Qunibi W, Moustafa M, Muenz LR, et al. A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: the Calcium Acetate Renegel Evaluation-2 (CARE-2) study. *American journal of kidney diseases : the official journal of the National Kidney Foundation*. 2008;51(6):952-965.
44. Palmer SC, Gardner S, Tonelli M, et al. Phosphate-Binding Agents in Adults With CKD: A Network Meta-analysis of Randomized Trials. *American journal of kidney diseases : the official journal of the National Kidney Foundation*. 2016;68(5):691-702.
45. Sekercioglu N, Thabane L, Diaz Martinez JP, et al. Comparative Effectiveness of Phosphate Binders in Patients with Chronic Kidney Disease: A Systematic Review and Network Meta-Analysis. *PloS one*. 2016;11(6):e0156891.
46. Jamal SA, Vandermeer B, Raggi P, et al. Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis. *Lancet*. 2013;382(9900):1268-1277.
47. Block GA, Wheeler DC, Persky MS, et al. Effects of Phosphate Binders in Moderate CKD. *Journal of the American Society of Nephrology : JASN*. 2012;23(8):1407-1415.

48. Ketteler M, Block GA, Evenepoel P, et al. Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update: what's changed and why it matters. *Kidney international*. 2017;92(1):26-36.
49. wu M, Tang R-n, Liu H, Pan M-m, Liu B-c. Cinacalcet ameliorates aortic calcification in uremic rats via suppression of endothelial-to-mesenchymal transition. *Acta Pharmacologica Sinica*. 2016;37(11):1423-1431.
50. Kawata T, Nagano N, Obi M, et al. Cinacalcet suppresses calcification of the aorta and heart in uremic rats. *Kidney international*. 2008;74(10):1270-1277.
51. Joki N, Nikolov IG, Caudrillier A, Mentaverri R, Massy ZA, Drueke TB. Effects of calcimimetic on vascular calcification and atherosclerosis in uremic mice. *Bone*. 2009;45 Suppl 1:S30-34.
52. Jung S, Querfeld U, Muller D, Rudolph B, Peters H, Kramer S. Submaximal suppression of parathyroid hormone ameliorates calcitriol-induced aortic calcification and remodeling and myocardial fibrosis in uremic rats. *J Hypertens*. 2012;30(11):2182-2191.
53. Rodriguez M, Aguilera-Tejero E, Mendoza FJ, Guerrero F, Lopez I. Effects of calcimimetics on extraskeletal calcifications in chronic kidney disease. *Kidney international Supplement*. 2008(111):S50-54.
54. Mendoza FJ, Martinez-Moreno J, Almaden Y, et al. Effect of Calcium and the Calcimimetic AMG 641 on Matrix-Gla Protein in Vascular Smooth Muscle Cells. *Calcified Tissue International*. 2011;88(3):169-178.
55. Lopez I, Aguilera-Tejero E, Mendoza FJ, et al. Calcimimetic R-568 decreases extraosseous calcifications in uremic rats treated with calcitriol. *Journal of the American Society of Nephrology : JASN*. 2006;17(3):795-804.
56. Nakayama K, Nakao K, Takatori Y, et al. Long-term effect of cinacalcet hydrochloride on abdominal aortic calcification in patients on hemodialysis with secondary hyperparathyroidism. *International Journal of Nephrology and Renovascular Disease*. 2014;7:25-33.
57. Cunningham J, Danese M, Olson K, Klassen P, Chertow GM. Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. *Kidney international*. 2005;68(4):1793-1800.
58. Raggi P, Chertow GM, Torres PU, et al. The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification

- in patients on hemodialysis. *Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association*. 2011;26(4):1327-1339.
59. Investigators TET. Effect of Cinacalcet on Cardiovascular Disease in Patients Undergoing Dialysis. *New England Journal of Medicine*. 2012;367(26):2482-2494.
 60. Floege J, Kubo Y, Floege A, Chertow GM, Parfrey PS. The Effect of Cinacalcet on Calcific Uremic Arteriopathy Events in Patients Receiving Hemodialysis: The EVOLVE Trial. *Clin J Am Soc Nephrol*. 2015;10(5):800-807.
 61. Moe SM, Abdalla S, Chertow GM, et al. Effects of Cinacalcet on Fracture Events in Patients Receiving Hemodialysis: The EVOLVE Trial. *Journal of the American Society of Nephrology : JASN*. 2015;26(6):1466-1475.
 62. Parfrey PS, Drueke TB, Block GA, et al. The Effects of Cinacalcet in Older and Younger Patients on Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial. *Clin J Am Soc Nephrol*. 2015;10(5):791-799.
 63. Hernandez FR, Canziani ME, Barreto FC, et al. The shift from high to low turnover bone disease after parathyroidectomy is associated with the progression of vascular calcification in hemodialysis patients: A 12-month follow-up study. *PloS one*. 2017;12(4):e0174811.
 64. London GM, Marty C, Marchais SJ, Guerin AP, Metivier F, de Vernejoul MC. Arterial calcifications and bone histomorphometry in end-stage renal disease. *Journal of the American Society of Nephrology : JASN*. 2004;15(7):1943-1951.
 65. Barreto DV, Barreto FC, Liabeuf S, et al. Vitamin D affects survival independently of vascular calcification in chronic kidney disease. *Clin J Am Soc Nephrol*. 2009;4(6):1128-1135.
 66. Pilz S, Iodice S, Zittermann A, Grant WB, Gandini S. Vitamin D status and mortality risk in CKD: a meta-analysis of prospective studies. *American journal of kidney diseases : the official journal of the National Kidney Foundation*. 2011;58(3):374-382.
 67. Zittermann A, Iodice S, Pilz S, Grant WB, Bagnardi V, Gandini S. Vitamin D deficiency and mortality risk in the general population: a meta-analysis of prospective cohort studies. *The American journal of clinical nutrition*. 2012;95(1):91-100.

68. Kidir V, Ersoy I, Altuntas A, et al. Effect of cholecalciferol replacement on vascular calcification and left ventricular mass index in dialysis patients. *Renal Failure*. 2015;37(4):635-639.
69. Aoshima Y, Mizobuchi M, Ogata H, et al. Vitamin D receptor activators inhibit vascular smooth muscle cell mineralization induced by phosphate and TNF-alpha. *Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association*. 2012;27(5):1800-1806.
70. Martinez-Moreno JM, Herencia C, Montes de Oca A, et al. Vitamin D modulates tissue factor and protease-activated receptor 2 expression in vascular smooth muscle cells. *FASEB journal : official publication of the Federation of American Societies for Experimental Biology*. 2016;30(3):1367-1376.
71. Cozzolino M, Brandenburg V. Paricalcitol and outcome: a manual on how a vitamin D receptor activator (VDRA) can help us to get down the "U". *Clin Nephrol*. 2009;71(6):593-601.
72. Molinari C, Uberti F, Grossini E, et al. 1alpha,25-dihydroxycholecalciferol induces nitric oxide production in cultured endothelial cells. *Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology*. 2011;27(6):661-668.
73. Mizobuchi M, Ogata H, Koiwa F, Kinugasa E, Akizawa T. Vitamin D and vascular calcification in chronic kidney disease. *Bone*. 2009;45 Suppl 1:S26-29.
74. Ellam T, Hameed A, ul Haque R, et al. Vitamin D deficiency and exogenous vitamin D excess similarly increase diffuse atherosclerotic calcification in apolipoprotein E knockout mice. *PloS one*. 2014;9(2):e88767.
75. Levin A, Tang M, Perry T, et al. Randomized Controlled Trial for the Effect of Vitamin D Supplementation on Vascular Stiffness in CKD. *Clinical Journal of The American Society of Nephrology: CJASN*.12(9):1447-1460.
76. Kumar V, Yadav AK, Lal A, et al. A Randomized Trial of Vitamin D Supplementation on Vascular Function in CKD. *Journal of the American Society of Nephrology : JASN*. 2017.
77. Kendrick J, Andrews E, You Z, et al. Cholecalciferol, Calcitriol, and Vascular Function in CKD: A Randomized, Double-Blind Trial. *Clin J Am Soc Nephrol*. 2017;12(9):1438-1446.
78. Russell RG, Smith R, Bishop MC, Price DA. Treatment of myositis ossificans progressiva with a diphosphonate. *Lancet*. 1972;1(7740):10-11.

79. Fleisch HA, Russell RG, Bisaz S, Muhlbauer RC, Williams DA. The inhibitory effect of phosphonates on the formation of calcium phosphate crystals in vitro and on aortic and kidney calcification in vivo. *European journal of clinical investigation*. 1970;1(1):12-18.
80. Synetos A, Toutouzas K, Benetos G, et al. Catheter based inhibition of arterial calcification by bisphosphonates in an experimental atherosclerotic rabbit animal model. *International journal of cardiology*. 2014;176(1):177-181.
81. Kramsch DM CC. The effect of agents interfering with soft tissue calcification and cell proliferation on calcific fibrous-fatty plaques in rabbits. *Circ Res* 1978 Apr;42(4):562-71.
82. Kramsch D, Aspen A, Rozler L. Atherosclerosis: Prevention by agents not affecting abnormal levels of blood lipids. *Science*. 1981;213(4515):1511-1512.
83. Tanko LB, Qin G, Alexandersen P, Bagger YZ, Christiansen C. Effective doses of ibandronate do not influence the 3-year progression of aortic calcification in elderly osteoporotic women. *Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA*. 2005;16(2):184-190.
84. Koshiyama H, Nakamura Y, Tanaka S, Minamikawa J. Decrease in carotid intima-media thickness after 1-year therapy with etidronate for osteopenia associated with type 2 diabetes. *The Journal of clinical endocrinology and metabolism*. 2000;85(8):2793-2796.
85. Toussaint ND, Lau KK, Strauss BJ, Polkinghorne KR, Kerr PG. Effect of Alendronate on Vascular Calcification in CKD Stages 3 and 4: A Pilot Randomized Controlled Trial. *American Journal of Kidney Diseases*.56(1):57-68.
86. Nitta K, Akiba T, Suzuki K, et al. Effects of cyclic intermittent etidronate therapy on coronary artery calcification in patients receiving long-term hemodialysis. *American Journal of Kidney Diseases*. 2004;44(4):680-688.
87. Hashiba H, Aizawa S, Tamura K, Shigematsu T, Kogo H. Inhibitory effects of etidronate on the progression of vascular calcification in hemodialysis patients. *Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy*. 2004;8(3):241-247.

88. Toussaint ND, Elder GJ, Kerr PG. Bisphosphonates in chronic kidney disease; balancing potential benefits and adverse effects on bone and soft tissue. *Clin J Am Soc Nephrol*. 2009;4(1):221-233.
89. Chan CT, Harvey PJ, Picton P, Pierratos A, Miller JA, Floras JS. Short-term blood pressure, noradrenergic, and vascular effects of nocturnal home hemodialysis. *Hypertension (Dallas, Tex : 1979)*. 2003;42(5):925-931.
90. Chan CT, Jain V, Picton P, Pierratos A, Floras JS. Nocturnal hemodialysis increases arterial baroreflex sensitivity and compliance and normalizes blood pressure of hypertensive patients with end-stage renal disease. *Kidney international*. 2005;68(1):338-344.
91. Van Eps CL, Jeffries JK, Anderson JA, et al. Mineral metabolism, bone histomorphometry and vascular calcification in alternate night nocturnal haemodialysis. *Nephrology (Carlton, Vic)*. 2007;12(3):224-233.
92. Yuen DA, Kuliszewski MA, Liao C, Rudenko D, Leong-Poi H, Chan CT. Nocturnal Hemodialysis Is Associated with Restoration of Early-Outgrowth Endothelial Progenitor-Like Cell Function. *Clinical Journal of the American Society of Nephrology : CJASN*. 2011;6(6):1345-1353.
93. Yuen D, Pierratos A, Richardson RM, Chan CT. The natural history of coronary calcification progression in a cohort of nocturnal haemodialysis patients. *Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association*. 2006;21(5):1407-1412.
94. Van Eps CL, Jeffries JK, Anderson JA, et al. Mineral metabolism, bone histomorphometry and vascular calcification in alternate night nocturnal haemodialysis. *Nephrology (Carlton, Vic)*. 2007;12(3):224-233.
95. Chan CT, Mardirossian S, Faratro R, Richardson RM. Improvement in lower-extremity peripheral arterial disease by nocturnal hemodialysis. *American journal of kidney diseases : the official journal of the National Kidney Foundation*. 2003;41(1):225-229.
96. Abedi SA, Tarzamni MK, Nakhjavani MR, Bohlooli A. Effect of renal transplantation on coronary artery calcification in hemodialysis patients. *Transplantation proceedings*. 2009;41(7):2829-2831.
97. Priyadarshini P, Aggarwal S, Guleria S, Sharma S, Gulati G. Short-term effects of renal transplantation on coronary artery calcification: A prospective study. *Saudi Journal of Kidney Diseases and Transplantation*. 2015;26(3):536-543.

98. Seyahi N, Cebi D, Altiparmak MR, et al. Progression of coronary artery calcification in renal transplant recipients. *Nephrology Dialysis Transplantation*. 2012;27(5):2101-2107.
99. Massy ZA, Nistor I, Apetrii M, et al. Magnesium-based interventions for normal kidney function and chronic kidney disease. *Magnes Res*. 2016;29(4):126-140.
100. Louvet L, Buchel J, Steppan S, Passlick-Deetjen J, Massy ZA. Magnesium prevents phosphate-induced calcification in human aortic vascular smooth muscle cells. *Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association*. 2013;28(4):869-878.
101. Montezano AC, Zimmerman D, Yusuf H, et al. Vascular smooth muscle cell differentiation to an osteogenic phenotype involves TRPM7 modulation by magnesium. *Hypertension (Dallas, Tex : 1979)*. 2010;56(3):453-462.
102. Xu J, Bai Y, Jin J, et al. Magnesium modulates the expression levels of calcification-associated factors to inhibit calcification in a time-dependent manner. *Experimental and Therapeutic Medicine*. 2015;9(3):1028-1034.
103. Bai Y, Zhang J, Xu J, et al. Magnesium prevents β -glycerophosphate-induced calcification in rat aortic vascular smooth muscle cells. *Biomedical Reports*. 2015;3(4):593-597.
104. Diaz-Tocados JM, Peralta-Ramirez A, Rodriguez-Ortiz ME, et al. Dietary magnesium supplementation prevents and reverses vascular and soft tissue calcifications in uremic rats. *Kidney international*. 2017;28:28.
105. Fang X, Wang K, Han D, et al. Dietary magnesium intake and the risk of cardiovascular disease, type 2 diabetes, and all-cause mortality: a dose-response meta-analysis of prospective cohort studies. *BMC medicine*. 2016;14(1):210.
106. Lutsey PL, Alonso A, Michos ED, et al. Serum magnesium, phosphorus, and calcium are associated with risk of incident heart failure: the Atherosclerosis Risk in Communities (ARIC) Study. *The American journal of clinical nutrition*. 2014;100(3):756-764.
107. Kieboom BC, Niemeijer MN, Leening MJ, et al. Serum Magnesium and the Risk of Death From Coronary Heart Disease and Sudden Cardiac Death. *Journal of the American Heart Association*. 2016;5(1).
108. Del Gobbo LC, Imamura F, Wu JH, de Oliveira Otto MC, Chiuve SE, Mozaffarian D. Circulating and dietary magnesium and risk of cardiovascular disease: a systematic

- review and meta-analysis of prospective studies. *The American journal of clinical nutrition*. 2013;98(1):160-173.
109. Qu X, Jin F, Hao Y, et al. Magnesium and the risk of cardiovascular events: a meta-analysis of prospective cohort studies. *PloS one*. 2013;8(3):e57720.
 110. Molnar AO, Biyani M, Hammond I, et al. Lower serum magnesium is associated with vascular calcification in peritoneal dialysis patients: a cross sectional study. *BMC Nephrology*. 2017;18(1):129.
 111. Pasch A, Farese S, Graber S, et al. Nanoparticle-based test measures overall propensity for calcification in serum. *Journal of the American Society of Nephrology*. 23(10):1744-1752.
 112. Tzanakis IP, Stamataki EE, Papadaki AN, Giannakis N, Damianakis NE, Oreopoulos DG. Magnesium retards the progress of the arterial calcifications in hemodialysis patients: a pilot study. *International urology and nephrology*. 2014;46(11):2199-2205.
 113. Bressendorff I, Hansen D, Schou M, Kragelund C, Brandi L. The effect of magnesium supplementation on vascular calcification in chronic kidney disease—a randomised clinical trial (MAGiCAL-CKD): essential study design and rationale. *BMJ Open*. 2017;7(6).
 114. Zaragatski E, Grommes J, Schurgers LJ, et al. Vitamin K antagonism aggravates chronic kidney disease-induced neointimal hyperplasia and calcification in arterialized veins: role of vitamin K treatment? *Kidney international*. 2016;89(3):601-611.
 115. Scheiber D, Veulemans V, Horn P, et al. High-Dose Menaquinone-7 Supplementation Reduces Cardiovascular Calcification in a Murine Model of Extraosseous Calcification. *Nutrients*. 2015;7(8):6991-7011.
 116. Mayer O, Jr., Seidlerova J, Wohlfahrt P, et al. Desphospho-uncarboxylated matrix Gla protein is associated with increased aortic stiffness in a general population. *Journal of Human Hypertension*. 30(7):418-423.
 117. Fusaro M, Noale M, Viola V, et al. Vitamin K, vertebral fractures, vascular calcifications, and mortality: VItamin K Italian (VIKI) dialysis study. *Journal of Bone and Mineral Research*. 2012;27(11):2271-2278.
 118. Schlieper G, Westenfeld R, Kruger T, et al. Circulating nonphosphorylated carboxylated matrix gla protein predicts survival in ESRD. *Journal of the American Society of Nephrology : JASN*. 2011;22(2):387-395.

119. Pilkey RM, Morton AR, Boffa MB, et al. Subclinical vitamin K deficiency in hemodialysis patients. *American journal of kidney diseases : the official journal of the National Kidney Foundation*. 2007;49(3):432-439.
120. Wyskida K, Zak-Golab A, Labuzek K, et al. Daily intake and serum concentration of menaquinone-4 (MK-4) in haemodialysis patients with chronic kidney disease. *Clinical Biochemistry*. 2015;48(18):1246-1251.
121. Neradova A, Schumacher SP, Hubeek I, Lux P, Schurgers LJ, Vervloet MG. Phosphate binders affect vitamin K concentration by undesired binding, an in vitro study. *BMC Nephrology*. 2017;18:149.
122. Kurnatowska I, Grzelak P, Masajtis-Zagajewska A, et al. Effect of vitamin K2 on progression of atherosclerosis and vascular calcification in nondialyzed patients with chronic kidney disease stages 3-5. *Polskie Archiwum Medycyny Wewnetrznej*. 2015;125(9):631-640.
123. Aoun M, Makki M, Azar H, Matta H, Chelala DN. High Dephosphorylated-Uncarboxylated MGP in Hemodialysis patients: risk factors and response to vitamin K(2), A pre-post intervention clinical trial. *BMC Nephrology*. 2017;18:191.
124. Westenfeld R, Krueger T, Schlieper G, et al. Effect of vitamin K2 supplementation on functional vitamin K deficiency in hemodialysis patients: a randomized trial. *American journal of kidney diseases : the official journal of the National Kidney Foundation*. 2012;59(2):186-195.
125. Holden RM, Booth SL, Day AG, et al. Inhibiting the progression of arterial calcification with vitamin K in HemoDialysis patients (iPACK-HD) trial: rationale and study design for a randomized trial of vitamin K in patients with end stage kidney disease. *Canadian Journal of Kidney Health and Disease*. 2015;2:17.
126. Evaluation of Vitamin K Supplementation for Calcific Uremic Arteriopathy. <https://ClinicalTrials.gov/show/NCT02278692>.
127. Cooper JN, Tepper P, Barinas-Mitchell E, Woodard GA, Sutton-Tyrrell K. Serum aldosterone is associated with inflammation and aortic stiffness in normotensive overweight and obese young adults. *Clinical and experimental hypertension (New York, NY : 1993)*. 2012;34(1):63-70.
128. de Rita O, Hackam DG, Spence JD. Effects of aldosterone on human atherosclerosis: plasma aldosterone and progression of carotid plaque. *The Canadian journal of cardiology*. 2012;28(6):706-711.

129. Sanz-Rosa D, Cediel E, de las Heras N, et al. Participation of aldosterone in the vascular inflammatory response of spontaneously hypertensive rats: role of the NFkappaB/IkappaB system. *J Hypertens*. 2005;23(6):1167-1172.
130. Jaffe IZ, Mendelsohn ME. Angiotensin II and aldosterone regulate gene transcription via functional mineralocorticoid receptors in human coronary artery smooth muscle cells. *Circ Res*. 2005;96(6):643-650.
131. Alesutan I, Voelkl J, Feger M, et al. Involvement Of Vascular Aldosterone Synthase In Phosphate-Induced Osteogenic Transformation Of Vascular Smooth Muscle Cells. *Scientific Reports*. 2017;7(1):2059.
132. Slight SH, Joseph J, Ganjam VK, Weber KT. Extra-adrenal mineralocorticoids and cardiovascular tissue. *Journal of molecular and cellular cardiology*. 1999;31(6):1175-1184.
133. Jaffe IZ, Tintut Y, Newell BG, Demer LL, Mendelsohn ME. Mineralocorticoid receptor activation promotes vascular cell calcification. *Arteriosclerosis, thrombosis, and vascular biology*. 2007;27(4):799-805.
134. Wu SY, Yu YR, Cai Y, et al. Endogenous aldosterone is involved in vascular calcification in rat. *Experimental biology and medicine (Maywood, NJ)*. 2012;237(1):31-37.
135. Lang F, Ritz E, Voelkl J, Alesutan I. Vascular calcification--is aldosterone a culprit? *Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association*. 2013;28(5):1080-1084.
136. Quach K, Ltvyn L, Baigent C, et al. The Safety and Efficacy of Mineralocorticoid Receptor Antagonists in Patients Who Require Dialysis: A Systematic Review and Meta-analysis. *American journal of kidney diseases : the official journal of the National Kidney Foundation*. 2016;68(4):591-598.
137. Safety and Cardiovascular Efficacy of Spironolactone in Dialysis-Dependent ESRD Trial. <https://ClinicalTrials.gov/show/NCT02285920>.
138. ALdosterone Antagonist Chronic HEModialysis Interventional Survival Trial. <https://ClinicalTrials.gov/show/NCT01848639>.
139. Agroyannis B, Tzanatos H, Vlahakos DV, Mallas E. Does long-term administration of sodium thiosulphate inhibit progression to renal failure in nephrocalcinosis? *Nephrology Dialysis Transplantation*. 2001;16(12):2443-2444.
140. Yatzidis H. Successful sodium thiosulphate treatment for recurrent calcium urolithiasis. *Clin Nephrol*. 1985;23(2):63-67.

141. Hayden MR, Tyagi SC, Kolb L, Sowers JR, Khanna R. Vascular ossification – calcification in metabolic syndrome, type 2 diabetes mellitus, chronic kidney disease, and calciphylaxis – calcific uremic arteriopathy: the emerging role of sodium thiosulfate. *Cardiovascular Diabetology*. 2005;4(1):4.
142. Mathews SJ, de las Fuentes L, Podaralla P, et al. Effects of Sodium Thiosulfate on Vascular Calcification in End-Stage Renal Disease: A Pilot Study of Feasibility, Safety and Efficacy. *American journal of nephrology*. 2011;33(2):131-138.
143. Adirekkiat S, Sumethkul V, Ingsathit A, et al. Sodium thiosulfate delays the progression of coronary artery calcification in haemodialysis patients. *Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association*. 2010;25(6):1923-1929.
144. A Phase 3 Clinical Trial of Intravenous Sodium Thiosulfate in Acute Calciphylaxis Patients. <https://ClinicalTrials.gov/show/NCT03150420>.
145. Grases F, Sanchis P, Perello J, et al. Phytate (Myo-inositol hexakisphosphate) inhibits cardiovascular calcifications in rats. *Frontiers in bioscience : a journal and virtual library*. 2006;11:136-142.
146. J. Perelló CS, M. Ketteler, F. Tur, E. Tur, B. Isern, P.H. Joubert, M.D. Ferrer. Intravenous SNF472 inhibits vitamin D induced cardiovascular calcification in rats. ASN; 2014; Philadelphia.
147. Effect of SNF472 on Progression of Cardiovascular Calcification in End-Stage-Renal-Disease (ESRD) Patients on Hemodialysis (HD). <https://ClinicalTrials.gov/show/NCT02966028>.
148. Verhulst A, Evenepoel P, D'Haese PC. Ligand trap for the activin type IIA receptor. The long-sought drug to overcome the calcification paradox in CKD? *Kidney international*.91(1):11-13.
149. Agapova OA, Fang Y, Sugatani T, Seifert ME, Hruska KA. Ligand trap for the Activin Type IIA receptor protects against vascular disease and renal fibrosis in mice with chronic kidney disease. *Kidney international*. 2016;89(6):1231-1243.
150. Sugatani T, Agapova OA, Fang Y, et al. Ligand trap of the activin receptor type IIA inhibits osteoclast stimulation of bone remodeling in diabetic mice with chronic kidney disease. *Kidney international*. 2017;91(1):86-95.
151. Davies MR, Lund RJ, Hruska KA. BMP-7 is an efficacious treatment of vascular calcification in a murine model of atherosclerosis and chronic renal failure. *Journal of the American Society of Nephrology : JASN*. 2003;14(6):1559-1567.

152. Kang YH, Jin JS, Yi DW, Son SM. Bone Morphogenetic Protein-7 Inhibits Vascular Calcification Induced by High Vitamin D in Mice. *The Tohoku Journal of Experimental Medicine*. 2010;221(4):299-307.
153. Mortazavi M, Moeinzadeh F, Saadatnia M, Shahidi S, McGee JC, Minagar A. Effect of magnesium supplementation on carotid intima-media thickness and flow-mediated dilatation among hemodialysis patients: a double-blind, randomized, placebo-controlled trial. *European neurology*. 2013;69(5):309-316.
154. Turgut F, Kanbay M, Metin MR, Uz E, Akcay A, Covic A. Magnesium supplementation helps to improve carotid intima media thickness in patients on hemodialysis. *International urology and nephrology*. 2008;40(4):1075-1082.
155. Spiegel DM, Farmer B. Long-term effects of magnesium carbonate on coronary artery calcification and bone mineral density in hemodialysis patients: A pilot study. *Hemodialysis International*. 2009;13(4):453-459.
156. Ishimura E, Okuno S, Kitatani K, et al. Significant association between the presence of peripheral vascular calcification and lower serum magnesium in hemodialysis patients. *Clin Nephrol*. 2007;68(4):222-227.
157. João Matias P, Azevedo A, Laranjinha I, et al. Lower Serum Magnesium Is Associated with Cardiovascular Risk Factors and Mortality in Haemodialysis Patients. *Blood Purification*. 2014;38(3-4):244-252.
158. Zaher MM, Abdel-Salam M, Abdel-Salam R, Sabour R, Morsy AA, Gamal D. Serum magnesium level and vascular stiffness in children with chronic kidney disease on regular hemodialysis. *Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia*. 2016;27(2):233-240.
159. Vukusich A, Kunstmann S, Varela C, et al. A randomized, double-blind, placebo-controlled trial of spironolactone on carotid intima-media thickness in nondiabetic hemodialysis patients. *Clin J Am Soc Nephrol*. 2010;5(8):1380-1387.

Figure Legends

Figure 1. Identified inhibitors and inducers of vascular calcification.

Figure 2. Mechanism of action of new therapeutics for vascular calcification.

Author Manuscript

Tables

Table 1. Clinical studies assessing the association between or effect of magnesium on vascular calcification or atherosclerotic vascular disease in patients with chronic kidney disease

Study	Study type	Population	Treatment	Duration	Primary outcome	Results
Mortaza <i>vi et al</i> 153	RCT	HD (n=54)	440mg Mg oxide thrice weekly versus placebo	6 months	cIMT	Decrease in cIMT in Mg group (from 0.84±0.13mm to 0.76±0.13mm, p=0.001)
Tzanakis <i>et al</i> (107)	RCT	HD (n=72)	Mg carbonate + Ca acetate versus Ca	12 months	SVCS	Improvement in small proportion of Mg group (n=4), no

			acetate alone			improvement in Ca group (n=0). Remainder of population either stable or worsening VC (n=ns)
Turgot <i>et al</i> ¹⁵⁴	RCT	HD (n=47)	Mg citrate (610mg) alternate daily vs Ca acetate	2 months	cIMT	Improvement in cIMT in Mg group (left cIMT p=0.001, right cIMT p=0.002)
Spiegel <i>et al</i> ¹⁵⁵	RCT	HD (n=7)	Mg carbonate +Ca carbonate as phosphate binder	18 months	CAC	No median percent change in CAC at completion (p=0.07)
Molnar <i>et al</i> ¹¹⁰	Cross- sectio nal	PD (n=80)	N/A	N/A	Lateral lumbar X-rays	Higher serum Mg (>0.8mmol/L) associated with lower AAC score

						(R ² = 0.006, unstandardized coefficient [B]=-7.81, p=0.003)
Ishimura <i>et al</i> ¹⁵⁶	Cross-sectional	Non-diabetic HD (n=390)	N/A	N/A	Hand X-ray	Serum mg significantly lower in patients with VC than those without (p<0.05)
Matias <i>et al</i> ¹⁵⁷	Prospective	Hemofiltration (n=206)	N/A	48 months	Plain X-ray	Significantly lower serum mg in patients with SVCS >=3 (p=0.008)
Zaher <i>et al</i> ¹⁵⁸	Cross-sectional	Children on HD (n=25)	N/A	N/A	cMIT	Higher cIMT in aorta and carotids in HD group than controls (p=0.034 and p=0.001 respectively)

Abbreviations: RCT, randomised controlled trial; HD, hemodialysis; PD, peritoneal dialysis; cIMT, carotid intimal medial thickness; Ca, calcium; Mg,

magnesium; CKD, chronic kidney disease; CAC, coronary artery calcification, SVCS, simple vascular calcification score; AE, adverse events

Table 2. Clinical studies assessing novel interventions for vascular calcification in patients with chronic kidney disease

Study	Study type	Population	Treatment	Duration	Primary outcome	Results
Vukusic <i>h et al</i> 159	RCT	HD (n=53)	50 mg spironolac tone thrice weekly post dialysis vs placebo	2 years	cIMT	Reduced progression of cIMT in spironolactone group arm (R CCA<0.03, L CCA <0.0001)
Adirekki <i>at et al</i> 143	Prospe ctive	HD (n=87)	Sodium thiosulfate twice weekly post dialysis	4 months	CAC	Reduced progression of CAC in treatment group (p=0.03). High rate of AE

Matthew <i>s et al</i> ¹⁴²	Prospective	HD (n=22)	Sodium thiosulfate post dialysis	5 months	CAC	No progression in mean annualized rate of change of VC in entire cohort.
Kurnato wska <i>et al</i> (117)	RCT	CKD (n=42)	90mcg K1+10mc g Vit D vs 10mcg Vit D	9 months	CAC, cIMT	Less cIMT increase in combined group (p=0.005). Similar increase in CAC in both groups (p=0.7)

Abbreviations: RCT, randomised controlled trial; HD, hemodialysis; PD, peritoneal dialysis; cIMT, carotid intimal medial thickness; Ca, calcium; Mg, magnesium; CKD, chronic kidney disease; CAC, coronary artery calcification, SVCS, simple vascular calcification score; AE, adverse events

Figure 1: Hypothesized Inhibitors and inducers of VC

Author Manuscript



